Lyon, France, February 24^th, 2023 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, today announces the initiation of IPH5201 CD39 blocking antibody phase 2 trial (MATISSE). The study entitled “Phase II Multicenter, Open Label, Non-randomized Study of Neoadjuvant and Adjuvant Treatment With IPH5201 and Durvalumab in Patients With Resectable, Early-stage (II to IIIA) Non-Small Cell Lung Cancer (MATISSE)” is an open-label, single-arm multicenter study (NCT05742607). As announced in 2022 (press release), the study will enroll 70 patients treated with IPH5201 (CD39 antibody) and Durvalumab (PDL1 antibody) plus standard of care chemotherapy before surgery followed by IPH5201 and Durvalumab.

About IPH5201 antibody

IPH5201 is a humanized CD39 blocking antibody. OREGA Biotech entered into an exclusive and worldwide License Agreement with Innate Pharma in 2016. The lead antibody has been further partnered with AstraZeneca in 2018. AstraZeneca conducted a multicenter, open-label, dose-escalation Phase 1 trial in advanced solid tumors (NCT04261075) with IPH5201 alone or in combination with durvalumab (anti PD-L1 antibody).

About OREGA Biotech

OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with new targets prior to enter into early-stage partnership or license agreements with larger biotech or pharmaceutical companies. The company is managed by Jeremy Bastid, CEO and Gilles Alberici, President.

Contact

Jeremy Bastid, Chief Executive Officer

Tel.: +33 (0)4 37 49 87 20

Email : jeremy.bastid@orega-biotech.com